Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience - do we need [18F]FDG.

CONCLUSIONS: [18F]FDG positive patients have statistically significant shorter survival parameters than [18F]FDG negative. The risk of progression in [18F]FDG positive vs [18F]FDG negative patients in one year follow up is comparable whereas in two-year follow up is nearly 2 times higher for [18F]FDG PET/CT positive patients.
PMID: 32293704 [PubMed - as supplied by publisher]

Source: Endokrynologia Polska - April 14, 2020 Category: Endocrinology Authors: Zemczak Katowice A, Kołodziej M, Gut P, Królicki L, Kos-Kudła B, Kamiński G, Ruchała M, Pawlak D, Kunikowska J Tags: Endokrynol Pol Source Type: research